Anthropic says its AI could transform biology, but IPO filing highlights limits

Anthropic and CEO Dario Amodei have said that their models could radically accelerate biology and drug discovery. In its IPO filing, however, the company says it must gain first-hand experience in scientific research and handle potentially hazardous materials, laboratory equipment, and regulatory requirements. It also describes the “Crispr-like” enzyme discovered by Claude as something that “might have the potential” to become a biotechnology tool, perhaps for gene editing.

Wired reports that researchers were skeptical of the discovery’s usefulness, and that a scientist studying similar enzymes suspected Claude may have used his research; Anthropic said neither the model nor its molecular biology team would have had access to that material. The company acknowledges that any discovery would still need to go through laboratory, animal, and human testing, a costly, lengthy, and uncertain process that may never generate revenue.